Pharmacokinetics and pharmacodynamics of benzbromarone in patients with hyperuricemia
10.13699/j.cnki.1001-6821.2024.12.024
- VernacularTitle:苯溴马隆在高尿酸血症患者中的药代动力学及药效学研究
- Author:
Li-Qin SUN
1
;
Yang FEI
;
Xiao-Yan XU
;
Qin-Hua LOU
Author Information
1. 杭州市富阳区第一人民医院内分泌科,浙江杭州 311400
- Keywords:
hyperuricemia;
benzbromarone;
pharmacokinetics;
pharmacodynamics
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(12):1813-1817
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the pharmacokinetics and pharmacodynamics of benzbromarone in patients with hyperuricemia(HUA).Methods Thirty patients with HUA were randomly divided into A,B and C groups,with 10 patients in each group.Three groups was given a single oral dose of benzbromarone 25,50 and 100 mg.After the single administration test,group B continued to take benzbromarone 50 mg orally once a day for 28 days.The concentration of benzbromarone in plasma was measured using liquid chromatography tandem mass spectrometry(LC-MS/MS)method,and the serum uric acid(SUA)level was measured by fully automated biochemical analyzer.Results The single oral administration of benzbromarone tablets exhibited linear pharmacokinetic characteristics within the range of 25-100 mg.The main pharmacokinetic parameters were as follows:t1/2 were(11.67±1.85),(12.84±1.22)and(13.25±1.02)h;tmax values were(2.84±0.15),(3.07±0.18)and(3.15±0.25)h;Cmax values were(2.21±0.85),(2.67±0.68)and(3.25±0.72)mg·L-1;AUC0-24h were(14.25±3.25),(18.20±3.34)and(19.25±3.44)mg·h·L-1,respectively.After continuous administration,there was no significant change in the degree and speed of drug absorption,and there was accumulation in the body.After 28 days of oral treatment with benzbromarone,the SUA levels of 10 HUA patients were significantly reduced,with 8 patients having SUA levels＜360 μmol·L-1.Conclusion A single oral dose of benzbromarone tablets exhibits linear pharmacokinetic characteristics at 25-100 mg,and continuous oral doses of benzbromarone tablets can significantly reduce SUA levels in patients with HUA.
